1492 Capital Management’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
Other funds holding CRL
1492 Capital Management's CRL Position: Q3 2026 in Review
1492 Capital Management reduced its Charles River Laboratories (CRL) stake by 2.4% in Q3 2026, selling an estimated $49.8K and leaving 7,552 shares worth $2.23M. The position accounts for 0.75% of the portfolio, ranked #47.
1492 Capital Management first reported a position in CRL in Q3 2014 and has held it in 26 quarters since. The position peaked at $2.39M in Q3 2021. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.
- 1492 Capital Management held 7,552 shares of Charles River Laboratories worth $2.23M as of Q3 2026.
- 1492 Capital Management sold 189 Charles River Laboratories shares in Q3 2026, an estimated $49.8K.
- Charles River Laboratories made up 0.75% of 1492 Capital Management's portfolio in Q3 2026, its #47 holding.
- 1492 Capital Management first reported a position in Charles River Laboratories in Q3 2014 and has held it in 26 quarters since.
- 1492 Capital Management's Charles River Laboratories position peaked at $2.39M in Q3 2021.
- 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.
Based on 1492 Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.